The Clinical Efficacy Of Mongolian Medicine Danggong-3 Capsule In The Treatment Of Stable Angina Pectoris Of Coronary Heart Disease And Quality Of Life Evaluation

Objective:To apply Mongolian medicine Danggong-3 capsule to treat patients with stable angina pectoris of coronary heart disease and to observe its clinical efficacy and its influence on the quality of life of patients.Methods:In this study,a randomized,double-blind,placebo-controlled research method was used to select all 116 stable angina outpatients who met the inclusion criteria from December 2018 to December 2020 in the Department of Cardiology and Health Care of the Inner Mongolia Autonomous Region Traditional Chinese Medicine Hospital.The patients were randomly divided into two groups,59 cases in the experimental group and 57 cases in the control group.On the basis of conventional Western medicine treatment,the two groups of patients took the Mongolian medicine Danggong-3 capsules and placebo,4 capsules a time,3 times a day for 8 weeks.The patient’s angina pectoris efficacy,TCM syndrome efficacy,electrocardiogram efficacy,Seattle Angina Pectoris Scale(SAQ)score,serum hs-CRP,and Hcy levels were evaluated at the first delivery and 8 weeks after the medication to further evaluate the Mongolian medicine Danggong-3.To further evaluate the effect of Mongolian medicine Danggong-3 capsule on the clinical efficacy and quality of life of patients.Results:1.In terms of the efficacy of angina pectoris,the angina pectoris efficacy scores of the two groups of patients were improved before and after treatment(P<0.05);after treatment,the angina efficacy scores of the experimental group were lower than those of the control group(P<0.05);angina pectoris always had after treatment The efficiency of the test group and the control group were 88.1% and73.2%,respectively,and there was a statistical difference between the two groups(P<0.05).2.In terms of the curative effect of TCM syndromes,the TCM syndrome scores of the two groups of patients improved before and after treatment(P<0.05);after treatment,the TCM syndrome scores of the experimental group were lower than those of the control group(P<0.05);The total effective rate of post-TCM syndrome curative effect was 84.7% and 66.8% in the experimental group and the control group respectively,and there was a statistical difference between the two groups(P<0.05).3.In terms of ECG curative effect,after treatment,the total effective rate of ECG of the experimental group and the control group were 45.8% and 40.4%,respectively.There was no statistical difference between the two groups(P>0.05).The improvement of the experimental group and the control group had no difference.Obvious difference.4.In terms of quality of life,after treatment,the two groups improved in physical activity limitation,angina stable state,angina pectoris,treatment satisfaction and disease awareness before and after treatment(P<0.05),The test group’s improvement in all aspects of the Seattle Angina Pectoris Scale was higher than that of the control group,and there was a statistical difference between the two groups(P<0.05).5.The serum levels of hs-CRP and Hcy in the two groups of patients decreased before and after treatment(P<0.05);After treatment,the hs-CRP and Hcy levels of the test group were lower than those of the control group,and there was a statistical difference between the two groups(P<0.05).Conclusion:The application of Mongolian medicine Danggong-3 capsules in the treatment of patients with stable angina pectoris of coronary heart disease has a significant clinical effect.It can not only reduce the symptoms of patients with stable angina pectoris,increase the total effective rate of the curative effect of angina pectoris,reduce the TCM syndrome score,and improve the total effective rate of TCM syndromes.It can also improve the quality of life of patients,reduce serum hs-CRP and Hcy levels,and has good safety.